Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
J-Pharma’s Biliary Tract Cancer Med Hits Mark in Japan PII Study
Japanese biotech J-Pharma said on January 23 that its L-type amino acid transporter 1 (LAT1) inhibitor nanvuranlat (JPH203) achieved the primary goal in a PII study conducted in Japan for the treatment of refractory, advanced biliary tract cancers. The primary…
To read the full story
Related Article
- J-Pharma Goes Public on TSE, Eyes Licensing of LAT1 Inhibitors
March 26, 2026
- Ohara Obtains Exclusive Rights to Biliary Tract Cancer Drug
April 26, 2019
- J-Pharma Initiates PI Trial of LAT1 Inhibitor
February 23, 2015
BUSINESS
- Tanabe to Sell Manufacturing Unit to Towa, Transfer 17 Products
July 6, 2026
- Espha Launches Generic Forxiga; Nipro AG Due in September
July 6, 2026
- GNI Targets Above-Industry Growth in Japan after Ayumi Buyout
July 3, 2026
- Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
- Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
July 3, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…